L. Martin

发表

30-day oral toxicity study of domoic acid in cynomolgus monkeys: lack of overt toxicity at doses approaching the acute toxic dose.

O. Pulido, F. Iverson, R. Mueller, 1997, Natural toxins.

Polychlorinated Biphenyl Congeners that Increase the Glucuronidation and Biliary Excretion of Thyroxine Are Distinct from the Congeners that Enhance the Serum Disappearance of Thyroxine

M. Gallo, K. Reuhl, C. Klaassen, 2012, Drug Metabolism and Disposition.

Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide

E. Perez, D. Gandara, P. Hesketh, 1996, Supportive Care in Cancer.

Single‐ and multiple‐dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2

S. Weir, T. Arumugham, W. Hahne, 1999, Biopharmaceutics & drug disposition.

Pharmacokinetics of Dolasetron after Oral and Intravenous Administration of Dolasetron Mesylate in Healthy Volunteers and Patients with Hepatic Dysfunction

W. Hahne, L. Martin, D. Dimmitt, 1997, Journal of clinical pharmacology.

Pharmacokinetics of intravenous dolasetron in cancer patients receiving high-dose cisplatin-containing chemotherapy.

W. Hahne, P. Plezia, L. Martin, 1999, American journal of therapeutics.

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1

S. Weir, T. Arumugham, W. Hahne, 1999, Biopharmaceutics & drug disposition.

Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers.

C R Benedict, C. Benedict, R. Arbogast, 1996, Journal of cardiovascular pharmacology.

Intravenous pharmacokinetics and absolute oral bioavailability of dolasetron in healthy volunteers: part 1

S. Weir, T. Arumugham, W. Hahne, 1999, Biopharmaceutics & drug disposition.